2,488
Views
9
CrossRef citations to date
0
Altmetric
Perspective

NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects

ORCID Icon
Pages 17-21 | Received 06 Feb 2021, Accepted 03 Jun 2021, Published online: 15 Jun 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Thanaporn Wattanakul, Palang Chotsiri, Ivan Scandale, Richard M. Hoglund & Joel Tarning. (2022) A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics. Expert Review of Clinical Pharmacology 15:8, pages 945-958.
Read now

Articles from other publishers (8)

Mina T. Kelleni. (2023) Evolution of SARS CoV-2 Omicron subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID restrictions. Journal of Infection 86:4, pages 405.
Crossref
Mina T. Kelleni. (2023) Real-life practice of the Egyptian Kelleni's protocol in the current tripledemic: COVID-19, RSV and influenza. Journal of Infection 86:2, pages 154-225.
Crossref
Mohamed Abuelazm, Ahmed Ghanem, Ahmed K. Awad, Ramadan Abdelmoez Farahat, Fatma Labieb, Basant E. Katamesh & Basel Abdelazeem. (2022) The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation 42:12, pages 1031-1047.
Crossref
Saloni, Dimple Kumari, Prabhat Ranjan & Tanmoy Chakraborty. (2022) A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory. Structural Chemistry 33:6, pages 2195-2204.
Crossref
Wanting Su, He Miao, Zhaotian Guo, Qianhui Chen, Tao Huang & Renyu Ding. (2022) Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis. Frontiers in Pharmacology 13.
Crossref
Panagiotis Zagaliotis, Anthi Petrou, George Mystridis, Athina Geronikaki, Ioannis Vizirianakis & Thomas Walsh. (2022) Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling. International Journal of Molecular Sciences 23:14, pages 8006.
Crossref
Christian Carlos Zurita‐Lizza & Pablo Alexis Doreski. (2022) Potential reversal of pulmonary vasoplegia by inhaled ibuprofenate in COVID‐19 pneumonia. Clinical and Translational Discovery 2:1.
Crossref
Mina T. Kelleni. (2021) COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators. Immunologic Research 69:5, pages 457-460.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.